Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Lophius Biosciences Achieves First Clinical Proof of Principle for T-Track TB


Lophius Biosciences Achieves First Clinical Proof of Principle for T-Track® TB for Detection of Active Tuberculosis and Receives Research Funding

Regensburg, Germany, November 8, 2012 - Lophius Biosciences, a leader in the field of novel T cell based diagnostic test systems, reported today about its first successfully concluded clinical Proof of Principle study with respect to detection of active tuberculosis (TB) using its novel T-Track® TB test which is based on Lophius Biosciences proprietary Reverse T Cell Technology (RT Technology).

The clinical Proof of Principle was concluded in India with a cohort of 44 patients. Results demonstrate that the T-Track® TB test was able to detect active TB in in 10 of 12 non-treated patients. Besides its high sensitivity and specificity the T-Track® TB test also demonstrated a remarkably short turnaround time of 2 days which compares favorably to currently used classical detection methods. In summary, these results imply that the T-Track® TB test could represent an innovative and fast detection approach for this area of strong medical need.

For further test development Lophius Biosciences has been awarded research funding of 140K EUR under the scope of the ZIM-solo-program from the German government. This funding should help to broaden the scope of the T-Track® TB tests with respect to detection of latent TB and potential patient-monitoring of treated TB subjects. The company will present first results at Medica mid November 2012 in Düsseldorf.

'We are very pleased to have accomplished clinical Proof of Principle for our second proprietary technology platform. Our short-term goal is geared towards test optimization and further validation in a bigger patient cohort' said Dr. Michael Lutz, CEO of Lophius Biosciences.


About Lophius Biosciences
Lophius Biosciences GmbH develops and markets innovative T cell based testing systems for diagnostics and possible therapy control in the fields of transplantation, infection and autoimmune diseases.


Contact
Lophius Biosciences GmbH
Josef-Engert-Str. 13
D-93053 Regensburg
Phone: +49 941 6309 1972
Email: info@lophius.de
www.lophius.de


Publisher Contact Information:

Lophius Biosciences
+49 941 6309 1972
info@lophius.de

Company profile of Lophius Biosciences
Past press releases of Lophius Biosciences.

Data


26,126
Tech investments
From our Online Data Service
16,881
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Sep 13N/AEnergy related
Sep 13€12.6MConsumer electronics
Sep 12€39.0MBiopharmaceuticals
Sep 12€2.3MInternet commerce
Sep 12€2.1MInternet services
Sep 12€4.0MMedical devices
Sep 12€9.0MSoftware development

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.